Navigation Links
Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Date:6/16/2010

s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='96457079';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.abbott.com/">www.abbott.com

Neurocrine Biosciences Forward Looking Statement

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are not limited to, risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to Phase III clinical trials; risk associated with the Company's dependence on Abbott for Phase III development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31,
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
2. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramals Healthcare Solutions Business
3. Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
4. Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott Declares 343rd Consecutive Quarterly Dividend
7. Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
8. Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
9. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
10. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
11. Abbott HIV Test Demonstrates Earlier Disease Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 On behalf ... its affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... secrets lawsuit against Genewiz Inc. in excess of $10 ... utilized GenScript,s trade secrets, and that it improperly hired ... an order denying motions for judgment notwithstanding the verdict, ...
(Date:2/26/2015)... MENLO PARK, Calif. , Feb. 26, 2015 /PRNewswire/ ... has released the latest version of the Governance ... organizations accomplish governance, risk and compliance (GRC) tasks across ... has also been updated to help customers better align ... Organizations of the Treadway Commission ) requirements. In response ...
(Date:2/26/2015)... 2015 The healthcare landscape is rapidly and radically ... Sullivan will host its 20 th Anniversary Medical ... 8 to 10, at the Hilton San Diego Resort and ... This event is a platform for global medical devices, ... disruptions and how to succeed in an uncertain future. ...
(Date:2/26/2015)... February 26, 2015 RURO, Inc., a ... FreezerPro® version 6.2 – the latest update to the ... is that of a quick and easy method to ... the latest version, RURO engineering has enhanced the system’s ... move large amounts of sample records. , "FreezerPro ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2
... April 29, 2011 Keryx Biopharmaceuticals, Inc. (NASDAQ: ... acquisition, development and commercialization of medically important pharmaceutical products ... "Company"), today announced its results for the first quarter ... 2011, the Company had cash, cash equivalents and investment ...
... Frost & Sullivan Europe New Product Innovation Award in ... its state-of-the-art, high precision Novelda Impulse Radar transceiver - ... transceiver is a cutting-edge radar transceiver that incorporates extremely ... penetration capabilities," remarks Frost & Sullivan Research Analyst V. ...
... 2011 Keryx Biopharmaceuticals (Nasdaq: KERX ) ... short-term clinical trial of Zerenex ™ (ferric citrate) ... patients on dialysis.  The Zerenex data was presented earlier ... being held in Las Vegas, Nevada, in an oral ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 4Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 2Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 3Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 4Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study 2Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study 3Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study 4
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... A study of 36 Spanish honeys from different floral ... honeydew have greater antioxidant properties than those produced by ... this month’s edition of the Journal of the Science ... important ingredients of many foods, and keenly sought in ...
... people will gladly remove excess body fat to improve their ... potential to repair defects and heal injuries in the body. ... Oslo in Norway has identified certain chemical marks that allow ... stem cells in liposuctioned fat, are best at regenerating tissue. ...
... Research Specialist II, and Linheng Li, Ph.D., Associate Investigator, are ... that clarifies how normal stem cells become cancer stem cells ... tumors. , The paper, "PTEN-deficient intestinal stem cells initiate ... on January 21. , The theory that cancer stem ...
Cached Biology News:Liposuctioned fat stem cells to repair bodies 2Linheng Li Lab documents the development of cancer stem cells 2
... system for detection of very low level ... Equipped with an extreme sensitive camera to ... plants in tumor research, infectious disease research, ... NightOWL is the only imager with a ...
... Analyzer and Sorter) large particle flow cytometers ... flow cytometry to applications that were not ... and sorting. Our instruments are based ... cytometers, but are designed to accommodate much ...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
...
Biology Products: